Medicilon assisted Bio-Thera's bispecific neutralizing antibody drug for injection BAT2022 for the treatment of new coronary pneumonia was approved for clinical use

On June 10, 2022, Bio-Thera Solutions, Ltd. (Bio-Thera) announced that BAT2022 for injection has obtained a clinical trial approval.  BAT2022 for injection is a bispecific neutralizing antibody independently developed by Bio-Thera, which is intended to be used for the treatment of new coronary pneumonia caused by the infection of the COVID19 and its mutants.

Reference:

Within 10 days, three Bispecific Antibody Drugs Assisted by Medicilon were Approved!

Development History and Market Prospects of Bispecific Antibodies

The Biological Analysis of Bispecific Atibody

Bio-Thera is committed to developing a new generation of innovative drugs and biosimilars for the treatment of tumors, autoimmune diseases, cardiovascular diseases and other major diseases that endanger human life or health.  As a leader in the research and development of next-generation antibody drugs, Bio-Thera has promoted a number of drug candidates into later-stage of clinical trials.

Since the founding of our company in 2004, Medicilon (Stock Code: 688202.SH) has grown into one of the professional drug discovery contract research organizations (CRO) in China.  Over the years, Medicilon keeps improving their services in biotechnology and pharmaceutical research.  Their services now span across medicinal chemistry, process chemistry, in vitro and in vivo DMPK, preclinical development and bioanalytical support.  By the end of 2021, Medicilon has provided new drug R&D services to more than 1,460 clients around the world, and participated in the R&D of 221 new drug projects that have been approved for clinical trials.  Medicilon is proud to contribute to human health in the globe.

Contact us:

Email：marketing@medicilon.com